STOK — Stoke Therapeutics Balance Sheet
0.000.00%
- $1.51bn
- $1.27bn
- $36.56m
- 77
- 27
- 88
- 71
Annual balance sheet for Stoke Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 287 | 220 | 230 | 201 | 217 |
| Net Total Receivables | 0.006 | 0.132 | 0.588 | 0.064 | 0.7 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 294 | 229 | 244 | 215 | 233 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.79 | 9.08 | 11.4 | 12.4 | 8.25 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 298 | 239 | 256 | 228 | 272 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11.4 | 17.1 | 31.4 | 30.8 | 40.1 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 11.8 | 21.1 | 71.2 | 68.8 | 42.5 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 286 | 218 | 185 | 160 | 229 |
| Total Liabilities & Shareholders' Equity | 298 | 239 | 256 | 228 | 272 |
| Total Common Shares Outstanding |